报价延迟最少15分钟:2026/05/31 06:42 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
614.78 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
40.96/47.74
|
|
企业价值
67.87B
|
| 资产负债 |
|
每股账面净值
299.73
|
| 现金流量 |
|
现金流量率
0.07
|
| 损益表 |
|
收益
14.34B
|
|
每股收益
124.93
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners. |
